Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CP1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: CP1. Displaying page 1 of 1.
    EudraCT Number: 2004-002504-15 Sponsor Protocol Number: NordCML002 Start Date*: 2004-12-01
    Sponsor Name:The Nordic CML Study Group
    Full Title: A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMAT...
    Medical condition: Newly diagnosed chronic myeloid leukemia (CML) belonging to intermedia (IR) or low risk (LR) by the Sokal prognostic score
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002420-15 Sponsor Protocol Number: RIC2006 Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Leipzig
    Full Title: Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Flud...
    Medical condition: Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Fludarabin bei älteren ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006972-31 Sponsor Protocol Number: Clo3o Start Date*: 2008-11-27
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Clinical phase II trial to evaluate the safety and efficacy of clofarabine and treosulfan conditioning prior to peripheral blood stem cells transplantation in paediatric and adult patients with adv...
    Medical condition: patients affected by advanced haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018865 Haematopoietic neoplasms (excl leukaemias and lymphomas) HLGT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000088-28 Sponsor Protocol Number: FHCRH2448 Start Date*: 2011-08-16
    Sponsor Name:Fred Hutchinson Cancer Research Center
    Full Title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablat...
    Medical condition: Graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10053239 Prophylaxis against graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005159-14 Sponsor Protocol Number: GC P#02.01.001 Start Date*: 2008-04-15
    Sponsor Name:Gamida Cell-Teva Joint Venture Ltd.
    Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ...
    Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10009015 Chronic myeloid leukemia LLT
    9.1 10001690 ALL LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 10:42:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA